This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aggarwal S., Somani V.K., Gupta S., Garg R., Bhatnagar R.: Development of novel multiepitope chimeric vaccine against anthrax. Med. Microbiol. Immunol.208, 185–195 (2019)AggarwalS.SomaniV.K.GuptaS.GargR.BhatnagarR.Development of novel multiepitope chimeric vaccine against anthraxMed. Microbiol. Immunol.208185195201910.1007/s00430-019-00577-x30671633Search in Google Scholar
Altboum Z., Gozes Y., Barnea A., Pass A., White M. Kobiler D.: Postexposure prophylaxis against anthrax: Evaluation of various treatment regimens in intranasally infected guinea pigs. Infect. Immun.70, 6231–6241 (2002)AltboumZ.GozesY.BarneaA.PassA.WhiteM.KobilerD.Postexposure prophylaxis against anthrax: Evaluation of various treatment regimens in intranasally infected guinea pigsInfect. Immun.7062316241200210.1128/IAI.70.11.6231-6241.200213032612379702Search in Google Scholar
Bernstein D.I., Jackson L., Patel S.M.: Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine, 32, 6284–6293 (2014)BernsteinD.I.JacksonL.PatelS.M.Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adultsVaccine3262846293201410.1016/j.vaccine.2014.08.076425029325239484Search in Google Scholar
Brossier F., Lévy. M., Landier A., Lafaye P., Mock M.: Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun.72, 6313–6317 (2004)BrossierF.Lévy.M.LandierA.LafayeP.MockM.Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodiesInfect. Immun.7263136317200410.1128/IAI.72.11.6313-6317.200452300215501759Search in Google Scholar
Chabot D.J., Joyce J., Caulfield M., Cook J., Hepler R., Wang S., Vietri N.J., Ruthel G., Shoop W., Pitt L.: Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys. Vaccine, 30, 846–852 (2012)ChabotD.J.JoyceJ.CaulfieldM.CookJ.HeplerR.WangS.VietriN.J.RuthelG.ShoopW.PittL.Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeysVaccine30846852201210.1016/j.vaccine.2011.12.01022172509Search in Google Scholar
Chabot D.J., Ribot W.J., Joyce J., Cook J., Helper R., Nahas D., Chua J., Friedlander A.M.: Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccine. Vaccine, 34, 4012–4016 (2016)ChabotD.J.RibotW.J.JoyceJ.CookJ.HelperR.NahasD.ChuaJ.FriedlanderA.M.Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccineVaccine3440124016201610.1016/j.vaccine.2016.06.03127329184Search in Google Scholar
Chomiczewski K.: Szczepionki przeciwko wąglikowi. Wakcynologia, Bielsko-Biała: 394–397 (2005)ChomiczewskiK.Szczepionki przeciwko wąglikowiWakcynologiaBielsko-Biała3943972005Search in Google Scholar
Doganay M., Demiraslan H.: Human anthrax as a re-emerging disease. Recent Pat. Antiinfect. Drug Discov.10, 10–29 (2015)DoganayM.DemiraslanH.Human anthrax as a re-emerging diseaseRecent Pat. Antiinfect. Drug Discov.101029201510.2174/1574891X10666150408162354Search in Google Scholar
Friedlnader A.M. Little S.F.: Advances in the development of next-generation anthrax vaccines. Vaccine, 27, 28–32 (2009)FriedlnaderA.M.LittleS.F.Advances in the development of next-generation anthrax vaccinesVaccine272832200910.1016/j.vaccine.2009.08.10219837282Search in Google Scholar
Gubbins M.J., Berry J.D., Corbett C.R., Mogridge J., Yuan X.Y., Schmidt L., Nicolas B., Kabani A., Tsang R.S.: Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of B. anthracis protective antigen. FEMS Immunol. Med. Microbiol.47, 436–443 (2006)GubbinsM.J.BerryJ.D.CorbettC.R.MogridgeJ.YuanX.Y.SchmidtL.NicolasB.KabaniA.TsangR.S.Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of B. anthracis protective antigenFEMS Immunol. Med. Microbiol.47436443200610.1111/j.1574-695X.2006.00114.x711035016872381Search in Google Scholar
Hanna P.: How anthrax kills. Science, 280 (5370):1671, 1673–1674 (1998)HannaP.How anthrax killsScience280 (5370):167116731674199810.1126/science.280.5370.1671c9660700Search in Google Scholar
Hicks C.W., Sweeney D.A., Cui X., Li Y., Eichacker P.Q.: An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med.38, 1092–1104 (2012)HicksC.W.SweeneyD.A.CuiX.LiY.EichackerP.Q.An overview of anthrax infection including the recently identified form of disease in injection drug usersIntensive Care Med.3810921104201210.1007/s00134-012-2541-0352329922527064Search in Google Scholar
Inglesby T.V., Tonat K. et al.: Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA, 287, 2236–2252 (2002)InglesbyT.V.TonatK.Anthrax as a biological weapon, 2002: updated recommendations for managementJAMA28722362252200210.1001/jama.287.17.223611980524Search in Google Scholar
Ivins B.E., Fellows P.F., Pitt M.L.M., Estep J.E., Welkos S.L., Worsham P.L. Friedlander A.M.:. Efficacy of standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med. Bull.87, 125–126 (1996)IvinsB.E.FellowsP.F.PittM.L.M.EstepJ.E.WelkosS.L.WorshamP.L.FriedlanderA.M.Efficacy of standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeysSalisbury Med. Bull.871251261996Search in Google Scholar
Ivins B.E., Welkos S.L.: Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol.4, 12–19 (1988)IvinsB.E.WelkosS.L.Recent advances in the development of an improved, human anthrax vaccineEur. J. Epidemiol.41219198810.1007/BF001526863128450Search in Google Scholar
Leppla S.H.: The anthrax toxin complex. In: Alouf J., Freer J.H., (eds). Sourcebook of bacterial protein toxins. London Academic Press. 277–302 (1991)LepplaS.H.The anthrax toxin complexIn:AloufJ.FreerJ.H.(eds).Sourcebook of bacterial protein toxinsLondon Academic Press2773021991Search in Google Scholar
Liu S., Moayeri M., Leppla S.H.: Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol.22, 317–325 (2014)LiuS.MoayeriM.LepplaS.H.Anthrax lethal and edema toxins in anthrax pathogenesisTrends Microbiol.22317325201410.1016/j.tim.2014.02.012404183424684968Search in Google Scholar
Liu X., Wang H. et al.: Genome sequence of Bacillus anthracis attenuated vaccine strain A16R used for human in China. J. Biotechnol.210, 15–16 (2015)LiuX.WangH.Genome sequence of Bacillus anthracis attenuated vaccine strain A16R used for human in ChinaJ. Biotechnol.2101516201510.1016/j.jbiotec.2015.06.40826116813Search in Google Scholar
Liu X., Wang D., Ren J., Tong Ch., Feng E., Wang X., Zhu L., Wang H.: Identification of the immunogenic spore and vegetative proteins of Bacillus anthracis vaccine strain A16R. PLoS One.8, e57959. DOI:10.1371/journal.pone.0057959. (2013).LiuX.WangD.RenJ.TongCh.FengE.WangX.ZhuL.WangH.Identification of the immunogenic spore and vegetative proteins of Bacillus anthracis vaccine strain A16RPLoS One.8e5795910.1371/journal.pone.00579592013359633823516421Open DOISearch in Google Scholar
Ma Y., Yu Y.Z., Yu-Feng Z., Qing X., Zhi-Wei S.: In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coli. Hum. Vaccine Immunother.9, 2371–2377 (2013)MaY.YuY.Z.Yu-FengZ.QingX.Zhi-WeiS.In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coliHum. Vaccine Immunother.923712377201310.4161/hv.25748398184623880942Search in Google Scholar
Manzulli V., Galante D. et al.: Evaluation of in vitro antimicrobial susceptibility of Bacillus anthracis strains isolated during anthrax outbreaks in Italy from 1984 to 2017. J. Vet. Sci.20, 58–62 (2019)ManzulliV.GalanteD.Evaluation of in vitro antimicrobial susceptibility of Bacillus anthracis strains isolated during anthrax outbreaks in Italy from 1984 to 2017J. Vet. Sci.205862201910.4142/jvs.2019.20.1.58635176130541185Search in Google Scholar
McComb R.C., Martchenko M.: Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen – The first step toward a rationally designed anthrax vaccine. Vaccine, 34, 13–19 (2016)McCombR.C.MartchenkoM.Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen – The first step toward a rationally designed anthrax vaccineVaccine341319201610.1016/j.vaccine.2015.11.02526611201Search in Google Scholar
Moayeri M., Leppla S.H., Vrentas C., Pomeranstev A.P., Liu S.: Anthrax pathogenesis. Annu. Rev. Microbiol.69, 185–208 (2015)MoayeriM.LepplaS.H.VrentasC.PomeranstevA.P.LiuS.Anthrax pathogenesisAnnu. Rev. Microbiol.69185208201510.1146/annurev-micro-091014-10452326195305Search in Google Scholar
Mourez M., Kane R.S., Mogridge J., Metallo S., Deschatelets P., Sellman B.R., Whitesides G. M., Collier R.J.: Designing a polyvalent inhibitor of anthrax toxin, Nat. Biotechnol.19, 985–961 (2001)MourezM.KaneR.S.MogridgeJ.MetalloS.DeschateletsP.SellmanB.R.WhitesidesG.M.CollierR.J.Designing a polyvalent inhibitor of anthrax toxinNat. Biotechnol.19985961200110.1038/nbt1001-958Search in Google Scholar
Ndumnego O.C., Köhler S.M., Crafford J., van Heerden H., Beyer W.: Comparative analysis of the immunogenic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in ruminant model. Vet. Immunol. Immunopathol.178, 14–21(2016)NdumnegoO.C.KöhlerS.M.CraffordJ.van HeerdenH.BeyerW.Comparative analysis of the immunogenic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in ruminant modelVet. Immunol. Immunopathol.1781421201610.1016/j.vetimm.2016.06.005Search in Google Scholar
Ndumnego O.C., Köehler S.M., Crafford J.E., Beyer W., van Heerden H.: Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model. Sci. Rep.8:16937. DOI: 10.1038/s41598-018-35382-8 (2018)NdumnegoO.C.KöehlerS.M.CraffordJ.E.BeyerW.van HeerdenH.Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse modelSci. Rep.81693710.1038/s41598-018-35382-82018Open DOISearch in Google Scholar
Powell A.G., Crozier J.E., Hodgson H., Galloway D.J., A case of septicemic anthrax in an intravenous drug user. BMC Infect Dis.11, 21 (2011)PowellA.G.CrozierJ.E.HodgsonH.GallowayD.J.A case of septicemic anthrax in an intravenous drug userBMC Infect Dis.1121201110.1186/1471-2334-11-21Search in Google Scholar
Quinn C.P., Marano N. et al.: A three – dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol.19, 1730–1745 (2012)QuinnC.P.MaranoN.A three – dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaquesClin. Vaccine Immunol.1917301745201210.1128/CVI.00324-12Search in Google Scholar
Sivko G.S., Stark G.V., Tordoff K.P., Taylor K.L., Glaze E., Van Raden M., Schiffer J.M., Hewitt J.A., Quinn C.P., Nuzum E.O.: Evaluation of early immune response-survival relationship in cynomolgus macaques after anthrax vaccine adsorbed vaccination and Bacillus anthracis spore challenge. Vaccine, 34, 6518–6528 (2016)SivkoG.S.StarkG.V.TordoffK.P.TaylorK.L.GlazeE.Van RadenM.SchifferJ.M.HewittJ.A.QuinnC.P.NuzumE.O.Evaluation of early immune response-survival relationship in cynomolgus macaques after anthrax vaccine adsorbed vaccination and Bacillus anthracis spore challengeVaccine3465186528201610.1016/j.vaccine.2016.04.048Search in Google Scholar
Tao P., Mahalingam M., Zhu J., Moayeri M., Kirtley M.L.: A bivalent anthrax-plague vaccine that can protect against two tier-1 bioterror pathogens, Bacillus anthracis and Yersinia pestis. Front. Immunol.8, 687 (2017)TaoP.MahalingamM.ZhuJ.MoayeriM.KirtleyM.L.A bivalent anthrax-plague vaccine that can protect against two tier-1 bioterror pathogens, Bacillus anthracis and Yersinia pestisFront. Immunol.8687201710.3389/fimmu.2017.00687Search in Google Scholar
Tao P., Mahalingam M., Zhu J., Moayeri M., Sha J., Lawrence W.S., Leppla S.H., Chopra A.K., Rao V.B.:. A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plague. mBio, 9, e01926-18 (2018)TaoP.MahalingamM.ZhuJ.MoayeriM.ShaJ.LawrenceW.S.LepplaS.H.ChopraA.K.RaoV.B.A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plaguemBio9e01926-18201810.1128/mBio.01926-18Search in Google Scholar
Turnbull P.C.B.: Anthrax vaccines: past, present and future. Vaccine, 9, 533–539 (1991)TurnbullP.C.B.Anthrax vaccines: past, present and futureVaccine9533539199110.1016/0264-410X(91)90237-ZSearch in Google Scholar
US Army Medical Research Institute of Infectious Diseases: Anthrax capsule vaccine completely protects monkeys from lethal inhalational anthrax. 27.07.2016, http://www.sciencedaily.com/releases/2016/06/160627125302.htm (5.12.2021)US Army Medical Research Institute of Infectious DiseasesAnthrax capsule vaccine completely protects monkeys from lethal inhalational anthrax. 27.07.2016http://www.sciencedaily.com/releases/2016/06/160627125302.htm (5.12.2021)Search in Google Scholar
Varshney A., Puranik N., Kumar M., Goel A.K.: The humoral immune response to various domains of protective antigen of Bacillus anthracis in cutaneous anthrax cases in India. Defence Sci. J.66, 645–650 (2016)VarshneyA.PuranikN.KumarM.GoelA.K.The humoral immune response to various domains of protective antigen of Bacillus anthracis in cutaneous anthrax cases in IndiaDefence Sci. J.66645650201610.14429/dsj.66.10805Search in Google Scholar
Veitch J., Kansara A., Bailey D., Kustos I.: Severe systemic Bacillus anthracis infection in an intravenous drug user. BMJ Case Rep.13, doi:10.1136/bcr-2013-201921 (2014)VeitchJ.KansaraA.BaileyD.KustosI.Severe systemic Bacillus anthracis infection in an intravenous drug userBMJ Case Rep.1310.1136/bcr-2013-2019212014392644824526196Open DOISearch in Google Scholar
Williamson E.D., Dyson E.H.: Anthrax prophylaxis: recent advances and future directions. Front. Microbial.6, 1009 (2015)WilliamsonE.D.DysonE.H.Anthrax prophylaxis: recent advances and future directionsFront. Microbial.61009201510.3389/fmicb.2015.01009458522426441934Search in Google Scholar
Woo S.J., Kang S.S., Park S.M., Yang J.S., Song M.K., Yan C.H., Han S.H.: Intranasal immunization with protective antigen of Bacillus anthracis induces a long-term immunological memory response. Mol. Immunol.67, 492–500 (2015)WooS.J.KangS.S.ParkS.M.YangJ.S.SongM.K.YanC.H.HanS.H.Intranasal immunization with protective antigen of Bacillus anthracis induces a long-term immunological memory responseMol. Immunol.67492500201510.1016/j.molimm.2015.08.00226278659Search in Google Scholar
Wright J.G, Quinn C.P. et al.: Effect of reduced dose schedules and intramuscular injection of anthrax adsorbed on immunological response and safety profile: A randomized trial. Vaccine, 32, 1019–1028 (2014)WrightJ.GQuinnC.P.Effect of reduced dose schedules and intramuscular injection of anthrax adsorbed on immunological response and safety profile: A randomized trialVaccine3210191028201410.1016/j.vaccine.2013.10.039906739024373307Search in Google Scholar
Żakowska D., Bartoszcze M., Kocik J. Nowe możliwości hamowania infekcji B. anthracis. Medycyna Wet.67, 665–668 (2011)ŻakowskaD.BartoszczeM.KocikJ.Nowe możliwości hamowania infekcji B. anthracisMedycyna Wet.676656682011Search in Google Scholar
Żakowska D., Kocik J., Bartoszcze M.: Wybrane kierunki badań nad szczepionkami przeciwko wąglikowi. Przegl. Epidemiol.63, 505–512 (2009)ŻakowskaD.KocikJ.BartoszczeM.Wybrane kierunki badań nad szczepionkami przeciwko wąglikowiPrzegl. Epidemiol.635055122009Search in Google Scholar